Prakt. lékáren. 2007; 3(6): 270-274

Farmakoterapie chronické obstrukční plicní nemoci

doc. MUDr. Jaromír Musil CSc
Pneumologická klinika 2. LF UK a FN Motol, Praha

Chronická obstrukční plicní nemoc (CHOPN) je definována jako léčitelné onemocnění, kterému lze předcházet a které má významné mimoplicní účinky, jež mohou přispívat k jeho závažnosti u jednotlivých nemocných. Jeho plicní složka je charakterizována omezeným průtokem vzduchu v průduškách (bronchiální obstrukcí), který není plně reverzibilní. Bronchiální obstrukce obvykle progreduje a je spojena s abnormální zánětlivou odpovědí na škodlivé částice a plyny.

Léčba lehké a středně těžké CHOPN (stadium I a II) zahrnuje vyloučení rizikových faktorů, aby se zabránilo progresi nemoci a farmakoterapii podávanou podle potřeby ke zvládnutí příznaků. Těžká forma (stadium III) a velmi těžká forma (stadium IV) často vyžaduje multioborový přístup.

Základem léčby je podávání bronchodilatancií. Léčba nedokáž

Published: January 20, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Musil J. Farmakoterapie chronické obstrukční plicní nemoci. Praktické lékárenství. 2007;3(6):270-274.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Adopted by the ATS Board of Directors, November, 1986. Am Rev Respir Dis 1987, 136, s. 225-244. Go to original source... Go to PubMed...
    2. Anthonisen NR, Connett JE, Kiley AP et al. Effect of smoking intervention and the use of inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Stud. JAMA, 1994, 272, s. 1495-1505. Go to original source...
    3. Anthonisen NR, Skeans MA, Wise RA et al. The effects of smoking cessation intervention od 14,5 year mortality: a randomized clinical trial. Ann Intern Med, 2005, 142, s. 233-239. Go to original source... Go to PubMed...
    4. Aubier M. Pharmacotherapy of respiratory muscles. Clin Chest Med, 1988, 9, s. 311-324. Go to original source... Go to PubMed...
    5. Carverley MA, Anderson JA, Celli B et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med, 2007, 356, s. 775-789. Go to original source... Go to PubMed...
    6. Decramer M, Celli B, Tashkin DP et al. Clinical trial design considerations in assessing long-term functional impacts Tiotropium in COPD: The UPLIFT trial COPD. J COPD, 2004, 1, s. 3093-3312. Go to original source... Go to PubMed...
    7. Dusser D, Bravo M-L, Iacono P et al. The effect of tiotropium on exacerbations and airflow in patiens with COPD. Eur Respir J, 2006, 27, s. 547-555. Go to original source... Go to PubMed...
    8. Cazzola M., Matera MG, Santangelo G et al. Salmeterol and formoterol in partiarlly reversible severe chronic obstructive pulmonary disease: a doseresponse study. Respir Med, 89, 5, s. 357-362. Go to PubMed...
    9. Fiore MC, Smith SS, Jorenby DE et al. The effectiveness of the nicotine patch for smoking cessation intervention. A meta-analysis. JAMA, 1994, 271, s. 1940-1947. Go to original source... Go to PubMed...
    10. Glynn TJ, Manley MW, Pechacek TF. Physician - initiated smoking cessation program: The National Cancer Institute trials. Progr Clin Biol Res, 1990, 333, s 11-25.
    11. Hay GJ, Stone P, Carter J et al. Bronchodilator responsibility, exercise performance nad breathlessness in stable chronic obstructive pulmonary disease. Eur Resp J, 1992, 5, 659-664. Go to original source...
    12. Jackson LA, Neuzil KM, Yu O et al. Effectiveness of pneumococcal polysaccaride vaccine in older adults. N Eng J Med, 2003, 348, s. 1747-1755. Go to original source... Go to PubMed...
    13. Johnston RN, McNeill RS, Smith DH et al. Five-year winter chemoprophylaxis for chronic bronchitis. Br Med J, 1969, 4, s. 265-269. Go to original source... Go to PubMed...
    14. Khoukaz G, Gross NJ. Effects of salmeterol on arterial blood gases in patients with stable chronic obstructive pulmonary disease. Comparison with albuterol and ipratropium. Am J Respir Crit Care Med, 1999, 160, s. 1028-1030. Go to original source... Go to PubMed...
    15. Kim CS, Kang TC. Comparative measurement of lung deposition of inhaled fine parcticles in normal subjects and patients with obstructive airway disease. AM J Respir Crit Care Med, 1997, 155, s. 899-905. Go to original source... Go to PubMed...
    16. McKay SE, Howie CA, Thompson AH et al. Value of theophylline treatment in patients handicapped by chronic obstructive pulmonary disease. Thorax, 1993, 48, s. 227-232. Go to original source... Go to PubMed...
    17. Murray CJL, Lopez AD. Evidence-based health policy - lessons from the Global Burden of Disease Study. Science 1996: 274, s. 740-743. Go to original source... Go to PubMed...
    18. Musil J, Vondra V, Kos s. et al. Světová iniciativa o Chronické obstrukční plicní nemoci. Překlad. Vltavín, 2007, 164 s.
    19. Nichol KL, Margolis KL, Wuorenma J et al. The efficaccy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Eng J Med, 1994, 331, s. 778-784. Go to original source... Go to PubMed...
    20. O´Donnel DE, Fluge T, Gerken F et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Resp J, 2004, 23, s. 832-840. Go to original source... Go to PubMed...
    21. O´Driscoll BR, Kay EA, Taylor RJ et al. A long-term prospective assessement of home nebulizer treatment. Respir Med, 1992, 86, s. 317-325. Go to original source... Go to PubMed...
    22. Pauwels RA, Lofdahl CG, Laitinen LA et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med, 1999, 340, s. 1948-1953. Go to original source... Go to PubMed...
    23. Sachs DP, Benowitz NL. Individualizing medical treatment for tobacco dependence. Eur Respir J, 1996, 9, s. 629-631. Go to original source... Go to PubMed...
    24. Shim CS, Williams MH. Bronchodilator response to oral aminophylline and terbutaline versus aerosol albuterol in patients with chronic obstructive pulmonary disease. Am J Med, 1983, 75, s. 697-701. Go to original source... Go to PubMed...
    25. Spencer S, Carverley PM, Burge PS et al. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Resp J, 2004, 23, s. 698-702. Go to original source... Go to PubMed...
    26. Shwartz JL. Review and evaluation of smoking cessation of smoking cessation methods: United States of Canada, 1978-1985. Bethesda, MD: National Institute of Health, 1985.
    27. Tashkin D, Kanner R, Bailey W et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double - blind, placebo controlled, randomized trial. Lancet, 2001, 375, s. 1571-1575. Go to original source... Go to PubMed...
    28. The Lung Health Study Research Group. Effects of ihnaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. Lung Health Study II. N Eng J Med, 2000, 343, s. 1902-1909. Go to original source... Go to PubMed...
    29. The tobacco use and dependence clinical practice guideline panel, staff, and consortium representatives. A clinical practice guideline for treating tobacco use and dependence. JAMA, 2000, 28, s. 3244-3254.
    30. The tobacco use and dependence clinical practice guideline panel, staff, and consortium representatives. A clinical practice guideline for treating tobacco use and dependence. JAMA, 2000, 28, s. 3244-3254.
    31. Tonstad S, Tonnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA, 2006, 296, sw., 64-71. Go to original source...
    32. Vincken W, van Noord JA, Greefhorst AP et al. Improved health outcomes in patients with COPD during 1 yr´s treatment with tiotropium. Eur Respir J, 2002, 19, s. 209-216. Go to original source... Go to PubMed...
    33. World Health Organisation. World health report. Geneva: World Health Organisation, 2000 i. Možno získat na adrese: http://www.who.int/whr/2000/en/statistics.htm.

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.